| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Targets pulmonary endothelial cells via selective adsorption of protein corona (e.g., fibrinogen), enabling lung-specific mRNA delivery after systemic administration.
|
|---|---|
| ln Vitro |
Enables efficient Cas9 mRNA and sgRNA co-delivery to pulmonary endothelial cells, facilitating CRISPR-based genome editing in the lung.
|
| ln Vivo |
IV-administered LNPs containing 306-N16B accumulate primarily in mouse lung endothelial cells, demonstrating robust in vivo lung transfection.
|
| Enzyme Assay |
LNPs are formulated by mixing ionizable lipid (306-N16B), helper lipids, cholesterol, and PEG-lipid in ethanol, then combining with mRNA in acidic buffer to form nanoparticles via rapid mixing.
|
| Cell Assay |
Transfect pulmonary endothelial cells by adding 306-N16B LNPs encapsulating reporter mRNA (e.g., Luciferase) to culture medium; measure expression after 24-48h via luminescence or fluorescence.
|
| Animal Protocol |
IV administer LNPs (e.g., 0.5-1 mg/kg mRNA) into mice; after 6-24h, harvest lungs and measure reporter gene expression or perform histology for endothelial-specific signals.
|
| ADME/Pharmacokinetics |
As an LNP component, it influences circulation time and biodistribution; the LNP formulation protects mRNA from degradation and enables endosomal escape for cytosolic delivery.
|
| Toxicity/Toxicokinetics |
No direct toxicity reported; LNP formulations may cause transient immune responses or inflammation; careful optimization needed to minimize off-target effects.
|
| References | |
| Additional Infomation |
This research tool is for non-human use, enabling studies of lung-selective genome editing, mRNA therapeutics, and targeted delivery systems. It exemplifies the growing field of organ-selective lipid nanoparticles.
|
| CAS # |
2803699-70-7
|
|---|---|
| Appearance |
Colorless to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~67.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
